Are you over 18 and want to see adult content?
More Annotations
![Во все тяжкие - смотреть онлайн все сезоны и серии](https://www.archivebay.com/archive/df2997ef-24c8-4d2b-b7f1-74f1b00dd023.png)
Во все тяжкие - смотреть онлайн все сезоны и серии
Are you over 18 and want to see adult content?
![Intercity bus search engine: Cheap bus ticket prices in Europe | busradar.com](https://www.archivebay.com/archive/ed1338a6-82d0-4e54-8250-e6837908d4ee.png)
Intercity bus search engine: Cheap bus ticket prices in Europe | busradar.com
Are you over 18 and want to see adult content?
![A complete backup of schrankgigant.de](https://www.archivebay.com/archive/9597e0a6-13e7-484b-ad70-ddfb8da0f388.png)
A complete backup of schrankgigant.de
Are you over 18 and want to see adult content?
![Experts in Metering Technology and Water Treatment - ProMinent](https://www.archivebay.com/archive/45c6b941-a9eb-4956-89e0-df72c50b5ff0.png)
Experts in Metering Technology and Water Treatment - ProMinent
Are you over 18 and want to see adult content?
![Superbits.org - Sveriges största bittorrent tracker.](https://www.archivebay.com/archive/9f1f9045-6ef0-449a-af68-871994406c3f.png)
Superbits.org - Sveriges största bittorrent tracker.
Are you over 18 and want to see adult content?
![Test de velocidad, ADSL, fibra y móvil | Testdevelocidad.info](https://www.archivebay.com/archive/96031401-8dfe-48f7-a610-41fde2903aad.png)
Test de velocidad, ADSL, fibra y móvil | Testdevelocidad.info
Are you over 18 and want to see adult content?
![Solar Permit Package Software | SolarDesignTool](https://www.archivebay.com/archive/824d9e9d-5f77-4f9c-b942-9610efc66b0e.png)
Solar Permit Package Software | SolarDesignTool
Are you over 18 and want to see adult content?
![European Web Hosting, VPS Hosting, Dedicated Servers](https://www.archivebay.com/archive/a5a70553-d5fd-441d-839b-6745b47465df.png)
European Web Hosting, VPS Hosting, Dedicated Servers
Are you over 18 and want to see adult content?
![Гелиос Плюс портал актуальных новостей и статей (ex NewsGG)](https://www.archivebay.com/archive/55219dee-8d5d-4925-9b0c-2ec171a29288.png)
Гелиос Плюс портал актуальных новостей и статей (ex NewsGG)
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of kotaksecurities.com](https://www.archivebay.com/archive2/f4c6d483-81ea-4198-846e-527fca357c65.png)
A complete backup of kotaksecurities.com
Are you over 18 and want to see adult content?
![A complete backup of myboracayguide.com](https://www.archivebay.com/archive2/1032a5d4-3a44-43d7-9cfa-6efb7a1fed5e.png)
A complete backup of myboracayguide.com
Are you over 18 and want to see adult content?
![A complete backup of trashknight.tumblr.com](https://www.archivebay.com/archive2/b4981886-3295-494f-bdb2-6ac7e1c4ac3b.png)
A complete backup of trashknight.tumblr.com
Are you over 18 and want to see adult content?
![A complete backup of mygracelesshope.tumblr.com](https://www.archivebay.com/archive2/feab05cf-5412-4353-8353-cba8e65b441a.png)
A complete backup of mygracelesshope.tumblr.com
Are you over 18 and want to see adult content?
![A complete backup of djsflac.blogspot.com](https://www.archivebay.com/archive2/cbedeb2d-8cfc-4991-98b4-23916033aa90.png)
A complete backup of djsflac.blogspot.com
Are you over 18 and want to see adult content?
![A complete backup of crossinstall.com](https://www.archivebay.com/archive2/554c4b72-8ea0-4770-97b5-9396b74648e8.png)
A complete backup of crossinstall.com
Are you over 18 and want to see adult content?
![A complete backup of telefonseelsorge.de](https://www.archivebay.com/archive2/05f250a1-7e1a-49d8-8438-1cf487b92655.png)
A complete backup of telefonseelsorge.de
Are you over 18 and want to see adult content?
![A complete backup of versiculosevangelicos.com](https://www.archivebay.com/archive2/d0548cf3-3875-47f9-99e1-211deb87e2f0.png)
A complete backup of versiculosevangelicos.com
Are you over 18 and want to see adult content?
Text
ROIVANT SCIENCES
Roivant Sciences is a biopharmaceutical company focused on realizing the full value of promising drug candidates to improve the lives ofpatients.
KINEVANT BY ROIVANT SCIENCES Kinevant – a wholly owned subsidiary of Roivant Sciences – is developing gimsilumab for the treatment and prevention of acute respiratory distress syndrome (ARDS) in patients with COVID-19. ARDS is a serious complication of COVID-19 that necessitates hospitalization and mechanical ventilation or other life supportmeasures.
ROIVANT SCIENCES AND MONTES ARCHIMEDES ACQUISITION CORP Transaction includes $411 million in trust at MAAC and a concurrent, fully committed $200 million PIPE financing from leading healthcare investors including Fidelity Management & Research Company LLC, Eventide Asset Management, Suvretta Capital, RTW Investments, LP, Viking Global Investors, and SB Management, a subsidiary of SoftBank Group Corp., as well as strategic investors ROIVANT ANNOUNCES DEVELOPMENT OF ANTI-GM-CSF MONOCLONAL Gimsilumab is a monoclonal antibody that targets GM-CSF, a pro-inflammatory cytokine found to be up-regulated in COVID-19 patients; Emerging clinical evidence in COVID-19 patients suggests that GM-CSF contributes to immunopathology caused by SARS CoV-2 in patients with or at risk of developing ARDS ROIVANT LAUNCHES LOKAVANT TO PROVIDE REAL-TIME AND Roivant Launches Lokavant to Provide Real-Time and Anticipatory Clinical Trial Monitoring SUMITOMO DAINIPPON PHARMA AND ROIVANT SCIENCES SIGN Alliance will include Roivant’s ownership interests in Myovant, Urovant, Enzyvant, Altavant, and Spirovant, a new company focused on developing innovative gene therapies for cystic fibrosis ARUVANT RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia; ARU-1801 has been designed to deliver a highly potent gene payload with enhanced anti-sickling properties, allowing for a Reduced Intensity Conditioning (RIC) regimen DERMAVANT SCIENCES TO PRESENT NEW DATA ON CERDULATINIB FOR BASEL, Switzerland, Dec. 6, 2018—Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the company will present new data on cerdulatinib during the 3rd Annual Inflammatory Skin Disease Summit (ISDS) taking place Dec. 12-15, 2018, in Vienna, Austria. ARUVANT APPOINTS WILLIAM CHOU AS CHIEF EXECUTIVE OFFICER Aruvant Appoints William Chou as Chief Executive Officer. Dr. Chou joins Aruvant from Novartis, where he most recently led the global commercial launch of Kymriah®, the first CAR-T cell therapy, in North America, Europe and Asia. Dr. Chou previously led the development and approval of Kymriah® for diffuse large B-cell lymphoma. 住友大日本製薬とロイヴァント科学が戦略的提携のための取引を…
Sumitovant is a global biopharmaceutical company with offices in New York City and London. Sumitovant is the parent company of five biopharma subsidiaries: Myovant, Urovant, Enzyvant, Altavant and Spirovant. Sumitovant’s promising pipeline is comprised of early- through late-stage investigational medicines across a range of diseaseareas
ROIVANT SCIENCES
Roivant Sciences is a biopharmaceutical company focused on realizing the full value of promising drug candidates to improve the lives ofpatients.
KINEVANT BY ROIVANT SCIENCES Kinevant – a wholly owned subsidiary of Roivant Sciences – is developing gimsilumab for the treatment and prevention of acute respiratory distress syndrome (ARDS) in patients with COVID-19. ARDS is a serious complication of COVID-19 that necessitates hospitalization and mechanical ventilation or other life supportmeasures.
ROIVANT SCIENCES AND MONTES ARCHIMEDES ACQUISITION CORP Transaction includes $411 million in trust at MAAC and a concurrent, fully committed $200 million PIPE financing from leading healthcare investors including Fidelity Management & Research Company LLC, Eventide Asset Management, Suvretta Capital, RTW Investments, LP, Viking Global Investors, and SB Management, a subsidiary of SoftBank Group Corp., as well as strategic investors ROIVANT ANNOUNCES DEVELOPMENT OF ANTI-GM-CSF MONOCLONAL Gimsilumab is a monoclonal antibody that targets GM-CSF, a pro-inflammatory cytokine found to be up-regulated in COVID-19 patients; Emerging clinical evidence in COVID-19 patients suggests that GM-CSF contributes to immunopathology caused by SARS CoV-2 in patients with or at risk of developing ARDS ROIVANT LAUNCHES LOKAVANT TO PROVIDE REAL-TIME AND Roivant Launches Lokavant to Provide Real-Time and Anticipatory Clinical Trial Monitoring SUMITOMO DAINIPPON PHARMA AND ROIVANT SCIENCES SIGN Alliance will include Roivant’s ownership interests in Myovant, Urovant, Enzyvant, Altavant, and Spirovant, a new company focused on developing innovative gene therapies for cystic fibrosis ARUVANT RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia; ARU-1801 has been designed to deliver a highly potent gene payload with enhanced anti-sickling properties, allowing for a Reduced Intensity Conditioning (RIC) regimen DERMAVANT SCIENCES TO PRESENT NEW DATA ON CERDULATINIB FOR BASEL, Switzerland, Dec. 6, 2018—Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the company will present new data on cerdulatinib during the 3rd Annual Inflammatory Skin Disease Summit (ISDS) taking place Dec. 12-15, 2018, in Vienna, Austria. ARUVANT APPOINTS WILLIAM CHOU AS CHIEF EXECUTIVE OFFICER Aruvant Appoints William Chou as Chief Executive Officer. Dr. Chou joins Aruvant from Novartis, where he most recently led the global commercial launch of Kymriah®, the first CAR-T cell therapy, in North America, Europe and Asia. Dr. Chou previously led the development and approval of Kymriah® for diffuse large B-cell lymphoma. 住友大日本製薬とロイヴァント科学が戦略的提携のための取引を…
Sumitovant is a global biopharmaceutical company with offices in New York City and London. Sumitovant is the parent company of five biopharma subsidiaries: Myovant, Urovant, Enzyvant, Altavant and Spirovant. Sumitovant’s promising pipeline is comprised of early- through late-stage investigational medicines across a range of diseaseareas
ROIVANT ANNOUNCES DEVELOPMENT OF ANTI-GM-CSF MONOCLONAL Gimsilumab is a monoclonal antibody that targets GM-CSF, a pro-inflammatory cytokine found to be up-regulated in COVID-19 patients; Emerging clinical evidence in COVID-19 patients suggests that GM-CSF contributes to immunopathology caused by SARS CoV-2 in patients with or at risk of developing ARDS ROIVANT SCIENCES PROVIDES CORPORATE UPDATE Roivant Sciences Provides Corporate Update. August 28, 2018. - Dr. Frank Torti, former partner at NEA, appointed Vant Investment Chair. - Rakhi Kumar promoted to Chief Accounting Officer. - NovaQuest makes $100 million strategic investment in Dermavant to advance development of tapinarof. - 30 rotational analysts in 2018 class selected from ROIVANT ANNOUNCES CREATION OF ROIVANT PHARMA AND ROIVANT Roivant to increase focus on incubating and launching new Vants, including new companies focused on earlier-stage and potentially transformative scientific platforms ROIVANT LAUNCHES ARUVANT SCIENCES AND ROIVANT FOUNDATION Aruvant’s pipeline anchored by RVT-1801, an investigational gene therapy for sickle cell disease and β-thalassemia; Clinical data for RVT-1801 to be presented in an oral session at ASH on December 3 rd; Roivant establishes nonprofit Roivant Foundation to improve access to therapies for patients with sickle cell disease in the developingworld
DERMAVANT ANNOUNCES CHANGES TO LEADERSHIP AND BOARD OF Dermavant Announces Changes to Leadership and Board of Directors. Jackie Fouse to step down as Executive Chair of Dermavant. Frank Torti named Chairman of the Board, and Myrtle Potter also joins board of directors. Dermavant prepares Phase 3 clinical program for lead drug, tapinarof, in 2019. BASEL, Switzerland, September 4, 2018 /PRNewswire ARUVANT APPOINTS WILLIAM CHOU AS CHIEF EXECUTIVE OFFICER Aruvant Appoints William Chou as Chief Executive Officer. Dr. Chou joins Aruvant from Novartis, where he most recently led the global commercial launch of Kymriah®, the first CAR-T cell therapy, in North America, Europe and Asia. Dr. Chou previously led the development and approval of Kymriah® for diffuse large B-cell lymphoma. ROIVANT SCIENCES ANNOUNCES $200 MILLION INVESTMENT ROUND BASEL, Switzerland and LONDON, United Kingdom, November 13, 2018 / PRNewswire / — Roivant Sciences today announced a $200 million equity financing. New investors include NovaQuest Capital Management, RTW Investments, and other large institutional asset managers. These new investors comprise a majority of the round. UROVANT SCIENCES TO HOST R&D DAY FOR INVESTORS AND BASEL, Switzerland & IRVINE, Calif. -- (BUSINESS WIRE) -- Jan. 15, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced that it will host its first R&D Day for investors and analysts in New York City on Thursday, February 7, 2019.The event will feature presentations by clinical experts DERMAVANTは、白斑のための局所二重JAK/SYK阻害剤セルドゥラ…
BASEL, Switzerland and LONG BEACH, Calif., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the first patient has been dosed in its Phase 2a vitiligo clinical trial for topical cerdulatinib. Cerdulatinib is a dual inhibitor of the Janus kinase(JAK) and spleen
新しい抗スーパーバグ生物学的SAL200のためのロイヴァントサ…
新しい抗スーパーバグ生物学的SAL200のためのロイヴァントサイエンスとiNtRONバイオサインライセンス契約. Roivant plans to initiate Phase 2 clinical trial in 2019. Agreement includes option to in-license additional anti-Gr (+) programs. BASEL, Switzerland, November 19, 2018 / PRNewswire / — RoivantROIVANT SCIENCES
Roivant Sciences is a biopharmaceutical company focused on realizing the full value of promising drug candidates to improve the lives ofpatients.
KINEVANT BY ROIVANT SCIENCES Kinevant – a wholly owned subsidiary of Roivant Sciences – is developing gimsilumab for the treatment and prevention of acute respiratory distress syndrome (ARDS) in patients with COVID-19. ARDS is a serious complication of COVID-19 that necessitates hospitalization and mechanical ventilation or other life supportmeasures.
ROIVANT SCIENCES AND MONTES ARCHIMEDES ACQUISITION CORP Transaction includes $411 million in trust at MAAC and a concurrent, fully committed $200 million PIPE financing from leading healthcare investors including Fidelity Management & Research Company LLC, Eventide Asset Management, Suvretta Capital, RTW Investments, LP, Viking Global Investors, and SB Management, a subsidiary of SoftBank Group Corp., as well as strategic investors ROIVANT LAUNCHES LOKAVANT TO PROVIDE REAL-TIME AND Roivant Launches Lokavant to Provide Real-Time and Anticipatory Clinical Trial Monitoring ROIVANT UNVEILS TARGETED PROTEIN DEGRADATION PLATFORM NEW YORK, BASEL, Switzerland, and SEOUL, South Korea, Dec. 6, 2020 / PRNewswire / -- Roivant Sciences today unveiled its targeted protein degradation platform which includes novel degraders for multiple diseases across oncology, immunology, and neurology. The first therapeutic candidate to emerge from this platform is on track toenter the
ARUVANT RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia; ARU-1801 has been designed to deliver a highly potent gene payload with enhanced anti-sickling properties, allowing for a Reduced Intensity Conditioning (RIC) regimen SUMITOMO DAINIPPON PHARMA AND ROIVANT SCIENCES SIGN Alliance will include Roivant’s ownership interests in Myovant, Urovant, Enzyvant, Altavant, and Spirovant, a new company focused on developing innovative gene therapies for cystic fibrosis ROIVANT SCIENCES PROVIDES CORPORATE UPDATE Roivant Sciences Provides Corporate Update. August 28, 2018. - Dr. Frank Torti, former partner at NEA, appointed Vant Investment Chair. - Rakhi Kumar promoted to Chief Accounting Officer. - NovaQuest makes $100 million strategic investment in Dermavant to advance development of tapinarof. - 30 rotational analysts in 2018 class selected from DERMAVANT SCIENCES TO PRESENT NEW DATA ON CERDULATINIB FOR BASEL, Switzerland, Dec. 6, 2018—Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the company will present new data on cerdulatinib during the 3rd Annual Inflammatory Skin Disease Summit (ISDS) taking place Dec. 12-15, 2018, in Vienna, Austria. ROIVANT ANNOUNCES CREATION OF ROIVANT PHARMA AND ROIVANT Roivant to increase focus on incubating and launching new Vants, including new companies focused on earlier-stage and potentially transformative scientific platformsROIVANT SCIENCES
Roivant Sciences is a biopharmaceutical company focused on realizing the full value of promising drug candidates to improve the lives ofpatients.
KINEVANT BY ROIVANT SCIENCES Kinevant – a wholly owned subsidiary of Roivant Sciences – is developing gimsilumab for the treatment and prevention of acute respiratory distress syndrome (ARDS) in patients with COVID-19. ARDS is a serious complication of COVID-19 that necessitates hospitalization and mechanical ventilation or other life supportmeasures.
ROIVANT SCIENCES AND MONTES ARCHIMEDES ACQUISITION CORP Transaction includes $411 million in trust at MAAC and a concurrent, fully committed $200 million PIPE financing from leading healthcare investors including Fidelity Management & Research Company LLC, Eventide Asset Management, Suvretta Capital, RTW Investments, LP, Viking Global Investors, and SB Management, a subsidiary of SoftBank Group Corp., as well as strategic investors ROIVANT LAUNCHES LOKAVANT TO PROVIDE REAL-TIME AND Roivant Launches Lokavant to Provide Real-Time and Anticipatory Clinical Trial Monitoring ROIVANT UNVEILS TARGETED PROTEIN DEGRADATION PLATFORM NEW YORK, BASEL, Switzerland, and SEOUL, South Korea, Dec. 6, 2020 / PRNewswire / -- Roivant Sciences today unveiled its targeted protein degradation platform which includes novel degraders for multiple diseases across oncology, immunology, and neurology. The first therapeutic candidate to emerge from this platform is on track toenter the
ARUVANT RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia; ARU-1801 has been designed to deliver a highly potent gene payload with enhanced anti-sickling properties, allowing for a Reduced Intensity Conditioning (RIC) regimen SUMITOMO DAINIPPON PHARMA AND ROIVANT SCIENCES SIGN Alliance will include Roivant’s ownership interests in Myovant, Urovant, Enzyvant, Altavant, and Spirovant, a new company focused on developing innovative gene therapies for cystic fibrosis ROIVANT SCIENCES PROVIDES CORPORATE UPDATE Roivant Sciences Provides Corporate Update. August 28, 2018. - Dr. Frank Torti, former partner at NEA, appointed Vant Investment Chair. - Rakhi Kumar promoted to Chief Accounting Officer. - NovaQuest makes $100 million strategic investment in Dermavant to advance development of tapinarof. - 30 rotational analysts in 2018 class selected from DERMAVANT SCIENCES TO PRESENT NEW DATA ON CERDULATINIB FOR BASEL, Switzerland, Dec. 6, 2018—Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the company will present new data on cerdulatinib during the 3rd Annual Inflammatory Skin Disease Summit (ISDS) taking place Dec. 12-15, 2018, in Vienna, Austria. ROIVANT ANNOUNCES CREATION OF ROIVANT PHARMA AND ROIVANT Roivant to increase focus on incubating and launching new Vants, including new companies focused on earlier-stage and potentially transformative scientific platforms ROIVANT UNVEILS TARGETED PROTEIN DEGRADATION PLATFORM NEW YORK, BASEL, Switzerland, and SEOUL, South Korea, Dec. 6, 2020 / PRNewswire / -- Roivant Sciences today unveiled its targeted protein degradation platform which includes novel degraders for multiple diseases across oncology, immunology, and neurology. The first therapeutic candidate to emerge from this platform is on track toenter the
ROIVANT ANNOUNCES DEVELOPMENT OF ANTI-GM-CSF MONOCLONAL Gimsilumab is a monoclonal antibody that targets GM-CSF, a pro-inflammatory cytokine found to be up-regulated in COVID-19 patients; Emerging clinical evidence in COVID-19 patients suggests that GM-CSF contributes to immunopathology caused by SARS CoV-2 in patients with or at risk of developing ARDS ROIVANT LAUNCHES RESPIVANT SCIENCES TO DEVELOP INNOVATIVE Respivant to be led by Bill Gerhart, former CEO of Patara Pharma and Elevation Pharmaceuticals; Respivant pipeline anchored by RVT-1601, an investigational therapeutic for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis SUMITOVANT BIOPHARMA CREATED AND LAUNCHED AS SUMITOMO Sumitomo Dainippon Pharma and Roivant Sciences complete strategic alliance and formation of new company, Sumitovant Biopharma, a wholly owned subsidiary of Sumitomo Dainippon Pharma SUMITOMO DAINIPPON PHARMA AND ROIVANT SCIENCES ENTER INTO Sumitomo Dainippon-Roivant Alliance (“Alliance”) encompasses up to 11 biopharmaceutical Vants with more than 25 innovative clinical programs and multiple potential product launches from 2020 to 2022, and access to key elements of Roivant’s proprietary technology platforms including DrugOme and ROIVANT ANNOUNCES CREATION OF ROIVANT PHARMA AND ROIVANT Roivant to increase focus on incubating and launching new Vants, including new companies focused on earlier-stage and potentially transformative scientific platforms BIONTECH AND GENEVANT SCIENCES SIGN STRATEGIC MRNA-FOCUSED Partnership combines Genevant’s industry-leading delivery technology and BioNTech’s cutting-edge mRNA drug discovery platform to develop best-in-class therapeuticsROIVANT SCIENCES
Warm autoimmune hemolytic anemia (WAIHA) is a rare hematologic disease in which autoantibodies mediate hemolysis, or the destruction of red blood cells. WAIHA approximately affects 42,000 people in the United States and 66,000 people in Europe. The clinical presentation is variable and most commonly includes non-specific symptoms of anemiasuch
LIGAND LICENSES GLUCAGON RECEPTOR ANTAGONIST PROGRAM TO Ligand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences. LGD-6972 to be a foundational program for Metavant, a new company formed by Roivant to pursue the development of innovative therapies for cardiometabolic diseases. SAN DIEGO (March 6, 2018) – Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced thesigning
ARUVANTが欧州血液学会(EHA)2021 VIRTUALCONGRESSでリードプ … Title: Towards Patient-Specific Dosing of Melphalan Conditioning for ARU-1801, A Novel Gene Therapy for Treatment of Sickle Cell Disease. Date and Time: Friday, June 11, 2021. Abstract: The abstract was published today at the EHA website. About Aruvant Sciences. Aruvant Sciences, part of the Roivant family of companies, is a clinical-stageROIVANT SCIENCES
Roivant Sciences is a biopharmaceutical company focused on realizing the full value of promising drug candidates to improve the lives ofpatients.
KINEVANT BY ROIVANT SCIENCES Kinevant – a wholly owned subsidiary of Roivant Sciences – is developing gimsilumab for the treatment and prevention of acute respiratory distress syndrome (ARDS) in patients with COVID-19. ARDS is a serious complication of COVID-19 that necessitates hospitalization and mechanical ventilation or other life supportmeasures.
ROIVANT SCIENCES AND MONTES ARCHIMEDES ACQUISITION CORP Transaction includes $411 million in trust at MAAC and a concurrent, fully committed $200 million PIPE financing from leading healthcare investors including Fidelity Management & Research Company LLC, Eventide Asset Management, Suvretta Capital, RTW Investments, LP, Viking Global Investors, and SB Management, a subsidiary of SoftBank Group Corp., as well as strategic investors ROIVANT LAUNCHES LOKAVANT TO PROVIDE REAL-TIME AND Roivant Launches Lokavant to Provide Real-Time and Anticipatory Clinical Trial Monitoring ARUVANT RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia; ARU-1801 has been designed to deliver a highly potent gene payload with enhanced anti-sickling properties, allowing for a Reduced Intensity Conditioning (RIC) regimen ROIVANT SCIENCES PROVIDES CORPORATE UPDATE Roivant Sciences Provides Corporate Update. August 28, 2018. - Dr. Frank Torti, former partner at NEA, appointed Vant Investment Chair. - Rakhi Kumar promoted to Chief Accounting Officer. - NovaQuest makes $100 million strategic investment in Dermavant to advance development of tapinarof. - 30 rotational analysts in 2018 class selected from SUMITOMO DAINIPPON PHARMA AND ROIVANT SCIENCES SIGN Alliance will include Roivant’s ownership interests in Myovant, Urovant, Enzyvant, Altavant, and Spirovant, a new company focused on developing innovative gene therapies for cystic fibrosis ALTAVANT SCIENCES PRESENTS DATA AT CHEST 2019 SUPPORTING CARY, N.C. and BASEL, Switzerland, Oct. 22, 2019 /PRNewswire/ — Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, today announced mechanistic preclinical pharmacodynamic and Phase 1 data supporting once-daily dosing of rodatristat ethyl for the treatment of pulmonary arterial hypertension (PAH). DERMAVANT SCIENCES TO PRESENT NEW DATA ON CERDULATINIB FOR BASEL, Switzerland, Dec. 6, 2018—Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the company will present new data on cerdulatinib during the 3rd Annual Inflammatory Skin Disease Summit (ISDS) taking place Dec. 12-15, 2018, in Vienna, Austria. AXOVANT ANNOUNCES GLOBAL LICENSING AGREEMENT FOR AXO-AAV Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD Program for Treatment of Oculopharyngeal Muscular Dystrophy and Broader Platform Collaboration with Benitec BiopharmaROIVANT SCIENCES
Roivant Sciences is a biopharmaceutical company focused on realizing the full value of promising drug candidates to improve the lives ofpatients.
KINEVANT BY ROIVANT SCIENCES Kinevant – a wholly owned subsidiary of Roivant Sciences – is developing gimsilumab for the treatment and prevention of acute respiratory distress syndrome (ARDS) in patients with COVID-19. ARDS is a serious complication of COVID-19 that necessitates hospitalization and mechanical ventilation or other life supportmeasures.
ROIVANT SCIENCES AND MONTES ARCHIMEDES ACQUISITION CORP Transaction includes $411 million in trust at MAAC and a concurrent, fully committed $200 million PIPE financing from leading healthcare investors including Fidelity Management & Research Company LLC, Eventide Asset Management, Suvretta Capital, RTW Investments, LP, Viking Global Investors, and SB Management, a subsidiary of SoftBank Group Corp., as well as strategic investors ROIVANT LAUNCHES LOKAVANT TO PROVIDE REAL-TIME AND Roivant Launches Lokavant to Provide Real-Time and Anticipatory Clinical Trial Monitoring ARUVANT RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia; ARU-1801 has been designed to deliver a highly potent gene payload with enhanced anti-sickling properties, allowing for a Reduced Intensity Conditioning (RIC) regimen ROIVANT SCIENCES PROVIDES CORPORATE UPDATE Roivant Sciences Provides Corporate Update. August 28, 2018. - Dr. Frank Torti, former partner at NEA, appointed Vant Investment Chair. - Rakhi Kumar promoted to Chief Accounting Officer. - NovaQuest makes $100 million strategic investment in Dermavant to advance development of tapinarof. - 30 rotational analysts in 2018 class selected from SUMITOMO DAINIPPON PHARMA AND ROIVANT SCIENCES SIGN Alliance will include Roivant’s ownership interests in Myovant, Urovant, Enzyvant, Altavant, and Spirovant, a new company focused on developing innovative gene therapies for cystic fibrosis ALTAVANT SCIENCES PRESENTS DATA AT CHEST 2019 SUPPORTING CARY, N.C. and BASEL, Switzerland, Oct. 22, 2019 /PRNewswire/ — Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, today announced mechanistic preclinical pharmacodynamic and Phase 1 data supporting once-daily dosing of rodatristat ethyl for the treatment of pulmonary arterial hypertension (PAH). DERMAVANT SCIENCES TO PRESENT NEW DATA ON CERDULATINIB FOR BASEL, Switzerland, Dec. 6, 2018—Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the company will present new data on cerdulatinib during the 3rd Annual Inflammatory Skin Disease Summit (ISDS) taking place Dec. 12-15, 2018, in Vienna, Austria. AXOVANT ANNOUNCES GLOBAL LICENSING AGREEMENT FOR AXO-AAV Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD Program for Treatment of Oculopharyngeal Muscular Dystrophy and Broader Platform Collaboration with Benitec Biopharma ROIVANT UNVEILS TARGETED PROTEIN DEGRADATION PLATFORM NEW YORK, BASEL, Switzerland, and SEOUL, South Korea, Dec. 6, 2020 / PRNewswire / -- Roivant Sciences today unveiled its targeted protein degradation platform which includes novel degraders for multiple diseases across oncology, immunology, and neurology. The first therapeutic candidate to emerge from this platform is on track toenter the
SUMITOMO DAINIPPON PHARMA AND ROIVANT SCIENCES SIGN Alliance will include Roivant’s ownership interests in Myovant, Urovant, Enzyvant, Altavant, and Spirovant, a new company focused on developing innovative gene therapies for cystic fibrosis ROIVANT LAUNCHES RESPIVANT SCIENCES TO DEVELOP INNOVATIVE Respivant to be led by Bill Gerhart, former CEO of Patara Pharma and Elevation Pharmaceuticals; Respivant pipeline anchored by RVT-1601, an investigational therapeutic for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis SUMITOVANT BIOPHARMA CREATED AND LAUNCHED AS SUMITOMO Sumitomo Dainippon Pharma and Roivant Sciences complete strategic alliance and formation of new company, Sumitovant Biopharma, a wholly owned subsidiary of Sumitomo Dainippon Pharma SUMITOMO DAINIPPON PHARMA AND ROIVANT SCIENCES ENTER INTO Sumitomo Dainippon-Roivant Alliance (“Alliance”) encompasses up to 11 biopharmaceutical Vants with more than 25 innovative clinical programs and multiple potential product launches from 2020 to 2022, and access to key elements of Roivant’s proprietary technology platforms including DrugOme and DERMAVANT SUBMITS NEW DRUG APPLICATION (NDA) TO FDA FOR Dermavant Submits New Drug Application (NDA) to FDA for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasis BIONTECH AND GENEVANT SCIENCES SIGN STRATEGIC MRNA-FOCUSED Partnership combines Genevant’s industry-leading delivery technology and BioNTech’s cutting-edge mRNA drug discovery platform to develop best-in-class therapeutics LIGAND LICENSES GLUCAGON RECEPTOR ANTAGONIST PROGRAM TO Ligand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences. LGD-6972 to be a foundational program for Metavant, a new company formed by Roivant to pursue the development of innovative therapies for cardiometabolic diseases. SAN DIEGO (March 6, 2018) – Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced thesigning
ROIVANT EXPANDS SENIOR LEADERSHIP WITH KEY HIRES BASEL, Switzerland and NEW YORK, May 16, 2018 /PRNewswire/ — Roivant Sciences today announced the expansion of its senior leadership team through the appointment of Dr. Salomon Azoulay as Chief Medical Officer and Adele Gulfo as Chief of Commercial Development. “I would like to extend a warm welcome to Sam and Adele,” said VivekRamaswamy
ダーマバント社は、プラーク乾癬の治療のためのタピナロフク…
ダーマバント社は、プラーク乾癬の治療のためのタピナロフクリームの第2b相臨床試験における二次的有効性と患者報告の結果をJAADで発表しました. May 26, 2020. LONG BEACH, Calif. & BASEL, Switzerland-- (BUSINESS WIRE) -- Dermavant Sciences, a clinical-stage biopharmaceuticalcompany
* Home
* Pipeline
* Leadership
* Partners
* News
* Contact us
* Join Us
REINVENTING
BIOPHARMA
Roivant is focused on rapidly developing innovative medicines through a novel form of industrial organization in R&D.ABOUT ROIVANT
Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. We have built 16 Vants to date and have raised over $3 billion to pursue our mission. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, sickle cell disease, and multiple rare and fatal pediatric conditions. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines. FOUNDER AND CEO VIVEK RAMASWAMY AT ROIVANT SCIENCES SECOND ANNUALPIPELINE DAY
OUR VANTS
MYOVANT
Dedicated to women’s health and prostate cancer.Learn More
OUR VANTS
ENZYVANT
Developing transformative therapies for patients with rare diseases.Learn More
OUR VANTS
AXOVANT
Finding new solutions in neurology.Learn More
OUR VANTS
METAVANT
Looking beyond the current options for cardiometabolic disorders.Learn More
OUR VANTS
UROVANT
Improving quality of life through advancements in urology.Learn More
OUR VANTS
DERMAVANT
Leading innovation in medical dermatology.Learn More
OUR VANTS
SINOVANT
Bringing medical innovation to China.Learn More
OUR VANTS
GENEVANT
Delivering results through RNA therapeutics.Learn More
OUR VANTS
ALTAVANT
Elevating patient-centric drug development.Learn More
OUR VANTS
ARBUTUS
Working towards a cure for hepatitis B.Learn More
OUR VANTS
RESPIVANT
Serving patients suffering from respiratory diseases.Learn More
OUR VANTS
IMMUNOVANT
Breaking barriers in immunology to restore patient health.Learn More
OUR VANTS
ARUVANT
Developing gene therapies for hematological conditions.Learn More
OUR VANTS
ALYVANT
Using data to connect patients to therapies.Learn More
OUR VANTS
DATAVANT
Organizing the world's healthcare data.Learn More
OUR VANTS
CYTOVANT
Developing novel and innovative cellular therapeutics in Asia.Learn More
OUR WORK
PIPELINE
We have a diverse pipeline of over 40 investigational drugs in 14 therapeutic areas across our family of companies.COMPANY
COMPOUND
INDICATION
PHASE
Company
Compound
Indication
PRECLIN
Phase 1
Phase 2
Phase 3
ENZYVANT
RVT-802
Pediatric Congenital Athymia3
MYOVANT
RELUGOLIX
Uterine Fibroids
3
UROVANT
VIBEGRON
Overactive Bladder
3
Overactive Bladder in Men with BPH3
DERMAVANT
TAPINAROF
Psoriasis
3
MYOVANT
RELUGOLIX
Endometriosis
3
Prostate Cancer
3
SINOVANT
LEFAMULIN
Community-Acquired Bacterial Pneumonia3
DERAZANTINIB
Intrahepatic Cholangiocarcinoma3
SNV-003
Delayed Graft Function3
Acute Kidney Injury
2
NARONAPRIDE
IBS-C
2
ALTAVANT
RODATRISTAT ETHYL
Pulmonary Arterial Hypertension2
ARUVANT
ARU-1801
Sickle Cell Disease and β-Thalassemia2
AXOVANT
AXO-LENTI-PD
Parkinson's Disease
2
CYTOVANT
CVT-DC-01
Acute Myeloid Leukemia2
DERMAVANT
TAPINAROF
Atopic Dermatitis
2
IMMUNOVANT
IMVT-1401
Myasthenia Gravis
2
Graves’ Ophthalmopathy2
METAVANT
RVT-1501
Diabetes
2
RVT-1502
Diabetes
2
MYOVANT
MVT-602
Female Infertility
2
RESPIVANT
RVT-1601
IPF with Chronic Cough2
AXOVANT
AXO-AAV-GM1
GM1 Gangliosidosis
2
AXO-AAV-GM2
Tay-Sachs and Sandhoff Diseases2
Arbutus
AB-506
Hepatitis B
1
AB-729
Hepatitis B
1
ALTAVANT
RODATRISTAT ETHYL
Idiopathic Pulmonary Fibrosis1
Sarcoidosis
1
DERMAVANT
DMVT-504
Primary Focal Hyperhidrosis1
CERDULATINIB
Atopic Dermatitis and Vitiligo1
UROVANT
URO-902
Overactive Bladder
1
VIBEGRON
IBS-Associated Pain
1
Arbutus
AB-452
Hepatitis B
Preclin
CYTOVANT
CVT-TCR-01
Oncologic MalignanciesPreclin
DERMAVANT
DMVT-501
Atopic Dermatitis
Preclin
DMVT-503
Acne Vulgaris
Preclin
ENZYVANT
RVT-801
Acid Ceramidase DeficiencyPreclin
GENEVANT
Additional pan-RNA ProgramsGenetic Disorders
Preclin
5 mRNA Programs
Rare Diseases
Preclin
×
PEDIATRIC CONGENITAL ATHYMIA Congenital athymia is a rare and deadly condition where children are born without a functional thymus, an essential part of the immune system, which leads to severe primary immunodeficiency. Congenital athymia is associated with complete DiGeorge Anomaly (cDGA), CHARGE syndrome, and FOXN1 deficiency. In the absence of treatment, children with this condition have no ability to fight infections. Currently, there are no approved FDA therapies for the congenital athymia. Enzyvant is working to change this situation by seeking FDA approval of RVT-802, an investigational tissue-based regenerative therapy designed to reconstitute the immune system for the treatment of T cell immunodeficiency resulting from congenital athymia. RVT-802 is the first program to be granted both Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy by the FDA.LEARN MORE HERE
×
UTERINE FIBROIDS
Uterine fibroids are non-cancerous tumors that develop from the muscle and connective tissue of the uterus. Approximately 25% of women of reproductive age have uterine fibroids, and 1 in 4 experience symptoms requiring treatment. Although uterine fibroids are benign tumors, they may cause debilitating symptoms including heavy and prolonged menstrual bleeding, anemia, and pelvic pain. Current treatments include hormonal contraceptives, GnRH agonists, and surgical interventions including myomectomy and hysterectomy. Relugolix is an oral, once-daily, gonadotropin-releasing hormone (GnRH) receptor antagonist. By inhibiting GnRH receptors in the anterior pituitary gland, relugolix rapidly reduces the circulating gonadotropin luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to the suppression of estrogen in women and testosterone in men. Suppression of these hormones improves the symptoms of uterine fibroids and endometriosis in women and decreases prostate-specific antigen (PSA) levels in men with advanced prostatecancer.
LEARN MORE HERE
×
OVERACTIVE BLADDER
Urovant’s investigational product candidate, vibegron, is an oral, once-daily, small molecule beta-3 agonist. The beta-3 adrenergic receptor is the most prevalent beta-adrenergic receptor subtype on the smooth muscle around the bladder. Bladder filling involves the relaxation of this muscle and the contraction of the urethral smooth muscle, while voiding involves contracting the bladder muscle and relaxation of the urethral muscle. Studies of isolated human bladder smooth muscle have shown that selective activation of the beta-3 adrenergic receptor results in smooth muscle relaxation. Therefore, beta-3 stimulation can increase bladder capacity and reduce the symptoms of overactive bladder (OAB). In March 2019, Urovant announced positive topline results from an international double-blind, placebo-controlled, multicenter Phase 3 clinical trial evaluating the efficacy and safety of vibegron 75mg in 1,518 adults with symptoms of overactive bladder. Urovant intends to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) by early2020.
In addition to OAB, vibegron is being developed for two additional potential indications: the treatment of OAB in men with benign prostatic hyperplasia (BPH) and the treatment of pain associated with irritable bowel syndrome (IBS).×
OAB IN MEN WITH BENIGN PROSTATIC HYPERPLASIA Urovant has initiatedan
international Phase 3 trial to evaluate the safety and efficacy of vibegron for symptoms of overactive bladder (OAB) in men who are receiving pharmacological treatment for benign prostatic hyperplasia (BPH). Vibegron is an investigational beta-3 agonist that has previously been evaluated in Phase 2b and Phase 3 studies in patients with overactive bladder. BPH is characterized by prostate enlargement, which can block the urethra and prevent normal urine flow, and is progressive with age. There are approximately 40 million men between the ages of 50 and 80 in the United States with BPH, approximately 4.5 million of whom are treated for their BPH symptoms. In addition, approximately 50% of BPH patients also suffer from overactive bladder. Medications used to treat BPH do not address OAB symptoms. Anticholinergics, a class of medication prescribed for OAB symptoms, are not indicated for OAB symptoms in men receiving pharmacological treatment for BPH and carry risks, including urinary retention, forthese patients.
×
PSORIASIS
Tapinarof is an investigational therapeutic aryl hydrocarbon receptor modulating agent (TAMA) for the treatment of psoriasis and atopic dermatitis. It has been evaluated as a topical therapy in multiple Phase 1 and Phase 2 studies involving over 800 human subjects. In a double-blind, placebo-controlled, global phase 2b dose-ranging study that enrolled 227 adults with plaque psoriasis, tapinarof demonstrated clinically meaningful, dose-dependent improvements over vehicle on the primary endpoint of the study, the proportion of treated patients who achieved Physician Global Assessment (PGA) scores of clear or almost clear (0 or 1) after 12 weeks of treatment with a minimum of 2-grade improvement in 5-point PGA score from baseline. 56% of patients in the tapinarof 1% once-daily group, and 46% of patients in the tapinarof 0.5% once-daily group, achieved 75% or greater improvement in Psoriasis Area and Severity Index scores (PASI 75) after 12 weeks of treatment, compared to 5% in the placebo once-daily group. The most frequently reported adverse events were folliculitis, contact dermatitis and headache. Efficacy assessments were made on a modified intent-to-treat population. PSOARING is Dermavant’s pivotal Phase 3 psoriasis clinical program for tapinarof, which consists of two identical, multi-center, randomized, vehicle-controlled, double-blind, parallel group studies—PSOARING 1 and PSOARING 2—to evaluate the safety and efficacy of tapinarof cream 1% dosed once daily (QD) for 12 weeks versus vehicle in adult patients aged 18-75 years diagnosed withplaque psoriasis.
The primary endpoint of both studies will be a Physician Global Assessment (PGA) score assessment of “clear” skin (score of 0) or “almost clear” skin (score of 1), plus at least a 2-grade improvement from baseline, at Week 12. Following the 12-week, vehicle-controlled portion of the PSOARING trials, patients will have the option to enroll in a separate, open-label extension study for an additional 40 weeks of treatment.×
ENDOMETRIOSIS
Endometriosis is a gynecological medical condition in which cells that normally line the uterus grow outside of the uterine cavity. An estimated 7.5 million women in the United States have endometriosis, and 3 in 4 experience symptoms requiring treatment. During the menstrual cycle, endometriosis lesions grow, differentiate, and shed into the abdomen, causing symptoms including non-menstrual pelvic pain and pain during menstruation (dysmenorrhea). Current treatments include hormonal contraceptives, danazol, GnRH agonists, and various surgical interventions for severe cases. Myovant is currently developing relugolix, an oral, once-daily, gonadotropin-releasing hormone (GnRH) receptor antagonist. By inhibiting GnRH receptors in the anterior pituitary gland, relugolix rapidly reduces the circulating gonadotropin luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to the suppression of estrogen in women and testosterone in men. Suppression of these hormones improves the symptoms of uterine fibroids and endometriosis in women and decreases prostate-specific antigen (PSA) levels in men with advanced prostate cancer. In a double-blind, placebo-controlled Phase 2 clinical trial in 487 patients with endometriosis, women who received relugolix experienced statistically significant reductions in non-menstrual and menstrual pelvic pain. Myovant has initiated a Phase 3 clinical program consisting of two international clinical trials, SPIRIT 1 and SPIRIT 2, to evaluate the efficacy and safety of relugolix in women with endometriosis-associated pain. Top-line results for both trials are expected in the first quarter of 2020.LEARN MORE HERE
×
PROSTATE CANCER
Prostate cancer is a malignant transformation of tissue within the male prostate gland. Often characterized by slow growth, prostate cancer is the second most prevalent form of cancer in men and the second leading cause of death due to cancer in men in the United States. Approximately 2.9 million men in the United States are currently living with prostate cancer, and 180,000 men are newly diagnosed each year. Symptoms of prostate cancer include increased urinary frequency, dysuria, hematuria, and nocturnal urination. Current treatments include combinations of surgery, radiation or proton beam therapy, androgen deprivation therapy, and chemotherapy. Myovant is currently developing relugolix, an oral, once-daily, gonadotropin-releasing hormone (GnRH) receptor antagonist. By inhibiting GnRH receptors in the anterior pituitary gland, relugolix rapidly reduces the circulating gonadotropin luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to the suppression of estrogen in women and testosterone in men. Suppression of these hormones improves the symptoms of uterine fibroids and endometriosis in women and decreases prostate-specific antigen (PSA) levels in men with advanced prostate cancer. In two randomized Phase 2 studies in approximately 228 men with advanced prostate cancer, oral once-daily relugolix suppressed serum testosterone to castrate levels anddecreased PSA.
Myovant has initiated a Phase 3 clinical trial, HERO, to evaluate the safety and efficacy of relugolix in treating men with advanced prostate cancer. Top-line safety and efficacy data are expected in the fourth quarter of 2019.LEARN MORE HERE
×
COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA Lefamulin is a novel antibiotic of the pleuromutilin class. Sinovant is initially developing lefamulin for community-acquired bacterial pneumonia (CABP), one of the leading causes of mortality in Mainland China. In preclinical studies, lefamulin has demonstrated a targeted spectrum of activity against the pathogens that most commonly cause CABP, including multi-drug resistant strains. Due to its novel mechanism of action, low incidence of cross-resistance between other antibacterial agents commonly used to treat CABP, and low propensity for bacterial resistance to develop, lefamulin has the potential to be used as a first-line empiric monotherapy for the treatment of CABP. Lefamulin has successfully completed two global Phase 3 studies in patients with moderate and severe CABP. Lefamulin has been granted Qualified Infectious Disease Product (QIDP) designation from the US FDA and is currently in preparation for an NDA in the United States and an MAA in Europe.×
INTRAHEPATIC CHOLANGIOCARCINOMA Derazantinib is a potent, orally administered inhibitor of the fibroblast growth factor receptor (FGFR) family, a key driver of cell proliferation, differentiation, and migration. Sinovant is initially developing derazantinib for the treatment of intrahepatic cholangiocarcinoma (iCCA), a devastating form of biliary tract cancer with high incidence in Greater China and parts of Asia and no approved therapies. In a Phase 1/2 study in patients with iCCA harboring FGFR2 gene fusions, treatment with derazantinib resulted in an objective response rate of 21%, nearly 3 times higher than standard-of-care chemotherapy. Derazantinib is currently being evaluated in a registration-enabling study in patients with FGFR2 fusion-positive second-line iCCA in the United States and Europe.×
DELAYED GRAFT FUNCTION Delayed graft function (DGF) is a form of acute kidney injury that manifests postoperatively in 20-30% of renal transplantation patients globally and is associated with a 40% decrease in long-term graft survival. In Greater China, persistent organ shortages have led to greater use of deceased donor kidneys, which is expected to drive increases in observed rates of DGF. SNV-003 is an investigational small molecule mimetic of hepatocyte growth factor (HGF) which Sinovant plans to develop in Greater Chinafor DGF.
×
ACUTE KIDNEY INJURY
Acute kidney injury (AKI) is characterized by an abrupt loss of kidney function and may be caused by a variety of factors. In the surgical setting, AKI is a common complication of open-heart surgery requiring cardiopulmonary bypass. Up to 30% of patients recovering from open-heart surgery experience an AKI-associated complication, resulting in a five-fold increased risk of death during hospitalization. Risk factors for AKI in the post-surgical setting include existing kidney disease, compromised heart function, exposure to nephrotoxic drugs, advanced age, and diabetes.×
IRRITABLE BOWEL SYNDROME WITH CONSTIPATION Naronapride is a novel prokinetic agent which accelerates gastric emptying and intestinal transit through 5HT4 receptor stimulation and D2 receptor inhibition. Sinovant is initially developing naronapride for the treatment of irritable bowel syndrome – constipation (IBS-C), a disease that affects millions of Chinese patients and for which few effective treatment options are available. Naronapride has been evaluated in over 900 subjects in multiple randomized controlled clinical studies and has demonstrated promising results in patients with gastroesophageal reflux disease (GERD), erosive esophagitis (EE), and chronic idiopathic constipation (CIC). Naronapride’s low systemic absorption and high specificity for 5HT4 and D2 receptors is thought to improve its safety and tolerability profile relative to other members of the class.×
PULMONARY ARTERIAL HYPERTENSION Pulmonary arterial hypertension (PAH) is a rare disease that affects the arteries in the lungs and the right side of the heart. PAH begins when tiny arteries in the lungs, called pulmonary arterioles, become narrowed, blocked or destroyed. This makes it harder for blood to flow through the lungs, and raises pressure within the lungs’ arteries. As the pressure builds, the heart’s lower right chamber (right ventricle) must work harder to pump blood through the lungs, eventually causing the heart muscle to weaken and eventually fail. PAH is a progressive, life-threatening illness. Rodatristat ethyl, a tryptophan hydroxylase (TPH) inhibitor that blocks the body’s peripheral production of serotonin, is currently in Phase 1 clinical development for pulmonary arterial hypertension with a number of additional indications being explored.×
SICKLE CELL DISEASE AND Β-THALASSEMIA ARU-1801 is an investigational gene therapy for sickle cell disease and β-thalassemia. ARU-1801 utilizes proprietary technology intended to increase functioning red blood cells by inserting a modified fetal hemoglobin gene into autologous stem cells through a lentiviral vector. Studies have indicated that sickle cell patients with elevated levels of fetal hemoglobin have fewer vaso-occlusive crises and hospitalizations, due in part to improved characteristics of fetal hemoglobin relative to adult hemoglobin. ARU-1801 is the only known clinical-stage gene therapy to deliver the gene encoding fetal hemoglobin, which has been modified to optimize oxygen carrying capacity and anti-sickling properties. ARU-1801 was developed in the laboratory of Dr. Punam Malik, Director of the Cincinnati Comprehensive Sickle Cell Center at Cincinnati Children’s. Preliminary clinical data from an ongoing Phase 1/2 study of ARU-1801 in patients with sickle cell disease conducted using a reduced-intensity conditioning (RIC) regimen enabled by the unique properties of modified fetal hemoglobin was presented by Dr. Malik in an oral presentation on Monday, December 3rd, at the Annual Meeting and Exposition of the American Society of Hematology in San Diego, CA.×
PARKINSON'S DISEASE
AXO-Lenti-PD is an investigational gene therapy for Parkinson’s disease that delivers three genes via a single lentiviral vector to encode a set of critical enzymes required for dopamine synthesis, with the goal of reducing variability and restoring steady levels of dopamine in the brain. The gene therapy aims to provide patient benefit for years following a single administration. Axovant announced positive preliminary results from the first cohort of patients in its ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD inMarch 2019.
LEARN MORE HERE
×
ATOPIC DERMATITIS
Tapinarof is an investigational therapeutic aryl hydrocarbon receptor modulating agent (TAMA) for the treatment of psoriasis and atopic dermatitis. It has been evaluated as a topical therapy in multiple Phase 1 and Phase 2 studies involving over 800 human subjects. In a double-blind, placebo-controlled global phase 2b dose-ranging study that enrolled 247 patients with atopic dermatitis, tapinarof demonstrated clinically meaningful, dose-dependent improvements over vehicle on the primary endpoint of the study, the proportion of patients with Investigator Global Assessment (IGA) scores of clear or almost clear (0 or 1) after 12 weeks of treatment with a minimum of 2-grade improvement in 5-point IGA score from baseline. Tapinarof was generally well tolerated. The most frequently reported adverse events were folliculitis, contact dermatitis and the common cold. Efficacy assessments were made on a modified intent-to-treat population.×
MYASTHENIA GRAVIS
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease characterized by weakness and fatigue of voluntary muscles. The disease is caused by pathogenic antibodies that target the neuromuscular junction, including the acetylcholine receptor (AChR) and the muscle specific tyrosine kinase receptor (MuSK), disrupting normal function. MG is a rare disease that affects approximately 46,000 to 66,000 people in the United States. MG is more prevalent in women and tends to affect younger women. In men, MG tends to affect anolder population.
The clinical course of MG is variable but usually progressive. Symptoms typically emerge in the eyes (e.g., drooping eyes, double-vision, blurred vision) and progress into the face, throat, and limbs. The chronic nature of MG requires patients to cope with fluctuating symptoms and multiple treatment regimens for management. Overall, the persistent muscle weakness associated with MG often negatively interferes with patients’ ability to engage in daily and physical activities, including demands of work, family, and socialfunctions.
Immunovant is developing IMVT-1401, a human recombinant anti-neonatal Fc receptor (FcRn) monoclonal antibody, for the treatment of IgG mediated diseases. The antibody facilitates the degradation of IgG by targeting FcRn and preventing endogenous IgG—including auto-antibodies—from binding. The increased catabolism curtails the harmful immune response exhibited by auto-antibodies. IMVT-1401 has completed a single and multiple ascending dose Phase 1 clinical trial in healthy volunteers. IMVT-1401 is being developed as a subcutaneous injection, providing a convenient and minimally invasive treatment option for patients.×
GRAVES’ OPHTHALMOPATHY Graves’ ophthalmopathy (GO), also known as thyroid eye disease, is an autoimmune disorder that affects the muscles and other tissues around the eyes. GO is most commonly caused by IgG autoantibodies that form against the thyroid-stimulating hormone receptor (TSHR). These antibodies, which also cause Graves’ disease, activate certain cell types, such as fibroblasts and adipocytes, that are present in the extraocular space, promoting inflammation and cellular expansion that result in the clinical manifestations of the disease. GO has an estimated annual incidence of 16 per 100,000 women and 2.9 per 100,000 men in North America and Europe. Approximately one in twenty patients with Graves’ disease will present with moderate-to-severe GO that is characterized by swelling and redness of the eyelids, proptosis (protrusion of the eyeball), double vision, and, in severe cases, corneal ulceration and decreased visual acuity. There are no therapies approved by the Food and Drug Administration (FDA) for GO. Immunovant is developing IMVT-1401, a human recombinant anti-neonatal Fc receptor (FcRn) monoclonal antibody, for the treatment of IgG mediated diseases. The antibody facilitates the degradation of IgG by targeting FcRn and preventing endogenous IgG—including auto-antibodies—from binding. The increased catabolism curtails the harmful immune response exhibited by auto-antibodies. IMVT-1401 has completed a single and multiple ascending dose Phase 1 clinical trial in healthy volunteers. IMVT-1401 is being developed as a subcutaneous injection, providing a convenient and minimally invasive treatment option for patients.×
DIABETES
RVT-1501 is the first clinical candidate in a new chemical class of oral agents called the glimins by the World Health Organization. RVT-1501 acts on the three key organs which play an important role in the current anti-diabetic treatment paradigm: the liver, muscles, and the pancreas. In several studies conducted to date, RVT-1501 has demonstrated potential glucose-lowering effects through increased insulin secretion in response to glucose, increased insulin sensitivity, and suppression of gluconeogenesis. RVT-1501's mechanism of action also has the potential to prevent diastolic dysfunction and to provide protective effects on beta cell survival and function. A total of 18 phase 1 and phase 2 clinical trials have been conducted studying RVT-1501 with over 1,200 patients with T2D in the U.S., Europe, and Japan, which have met their primary and secondary endpoints, including a statistically significant decrease of HbA1c and fasting plasma glucose versus placebo with a favorable side effect profile. Metavant has initiated differentiation studies to confirm RVT-1501's therapeutic potential in underserved patient populations with unfulfilled medical needs, such as those with chronic kidneydisease.
×
DIABETES
RVT-1502 (formerly LGD-6972) is a novel, orally-bioavailable, small molecule, glucagon receptor antagonist (GRA). Overproduction of glucose by the liver is an important cause of hyperglycemia (high glucose levels) in patients with diabetes and is due in part to inappropriately elevated levels of glucagon. GRAs may lower glucose levels by reducing the production of glucose by the liver. RVT-1502 has been tested in multiple phase 1 and 2 studies, with pharmacokinetics supporting once-daily oral dosing. In those studies, statistically significant reductions in fasting plasma glucose, postprandial glucose, and HbA1c in patients with type 2 diabetes havebeen observed.
A phase 2 clinical study evaluating RVT-1502 as an adjunct to diet and exercise in patients with type 2 diabetes showed statistically significant improvement in hemoglobin A1c (HbA1c) (p < 0.001) after 12 weeks of treatment at all doses tested compared to placebo. In the study, RVT-1502 was observed to be well-tolerated by study subjects.×
FEMALE INFERTILITY
Approximately 25% of infertile women have problems related to ovulation, including the inability to produce fully matured eggs or release an egg from the ovary (i.e., “ovulate”). In the course of treating infertility related to anovulation, fertility specialists use a group of medications to temporarily correct ovulatory problems and increase a woman’s chance for pregnancy. These and related procedures are broadly termed Assisted Reproductive Technology, or ART. According to the CDC, approximately 208,000 cycles of ART were performed in the US in 2014 (the most recent year data is available), with millions more performed worldwide. Myovant is developing MVT-602, an oligopeptide kisspeptin agonist, as a potential treatment for female infertility in women as part of assisted reproduction. Kisspeptin is a naturally-occurring peptide that stimulates GnRH release and is required for puberty and maintenance of normal reproductive function, including production of sperm, follicular maturation and ovulation, and production of estrogen and progesterone in women and testosterone in men. In a Phase 1 study in healthy female volunteers conducted in the second half of 2017, a single injection of MVT-602 was observed to cause a dose-dependent luteinizing hormone surge. In May 2018, Myovant initiated a Phase 2a clinical trial in healthy female volunteers to characterize the dose response curve in the controlled ovarian stimulation setting prior to studying MVT-602 in infertile woman seeking pregnancy. Top-line results are expected in the first half of 2019.LEARN MORE HERE
×
IDIOPATHIC PULMONARY FIBROSIS WITH CHRONIC COUGH RVT-1601 (formerly PA101) is a novel formulation of inhaled cromolyn sodium delivered through a proprietary nebulizer device designed to yield high lung deposition and distribution. In a completed Phase 2a trial, RVT-1601 demonstrated a statistically significant reduction in daytime and 24-hour cough frequency among idiopathic pulmonary fibrosis (IPF) patients versus placebo after 14 days of treatment. This reduction was supported by positive trends in cough-specific quality of life and cough severity, as assessed by patients in the study. The therapy was well tolerated, with no significant treatment-related adverse events reported in clinical studies to date. Respivant has initiated a Phase 2b study to identify the optimal dosefor RVT-1601.
×
GM1 GANGLIOSIDOSIS
AXO-AAV-GM1 delivers a functional copy of the _GLB1_ gene via an adeno-associated viral (AAV) vector, AAV9, which is effective in crossing the blood-brain barrier and transducing neurons, with the goal of restoring β-gal enzyme activity for the treatment of GM1 gangliosidosis. The gene therapy is delivered intravenously, which has the potential to broadly transduce the central nervous system and treat peripheral manifestations of the disease. In preclinical studies, AXO-AAV-GM1 was shown to improve β-gal enzyme activity, reduce GM1 ganglioside accumulation, improve neuromuscular function, and extend survival. Magnetic resonance imaging (MRI) of felines with GM1 gangliosidosis treated with GM1 gene therapy showed normal brain architecture through at least two years of age.×
TAY-SACHS/SANDHOFF DISEASE AXO-AAV-GM2 delivers functional copies of the HEXA and HEXB genes via two, co-administered AAVrh8 vectors delivered directly to the central nervous system with the goal of restoring Hex A enzyme activity to address both Tay-Sachs and Sandhoff diseases. The preclinical data for AXO-AAV-GM2 in murine models showed dose-dependent increases in Hex A enzyme activity, reductions of GM2 gangliosides in the brain and prolonged survival rates. Axovant reported three-month data from an investigator-initiated study administering investigational AXO-AAV-GM2 gene therapy in a patient with advanced infantile Tay-Sachs disease in March 2019.LEARN MORE HERE
×
IDIOPATHIC PULMONARY FIBROSIS Idiopathic pulmonary fibrosis is an interstitial lung disease that is diagnosed in approximately 22,000 people annually in the U.S. Its incidence is higher in men than women. Median survival for patients with IPF can be less than 3.5 years from diagnosis. IPF is triggered by an unknown insult in which functional lung tissue is replaced with fibrous scar tissue. A normal response to injury involves the upregulation of factors that recruit immune cells and promote the production of epithelial and connective tissue. This response subsides on its own. In patients with IPF, this repair process continues unabated, leading to excessive production of fibrotic and extracellular matrix (ECM) proteins. Over time, this leads to a thickening of alveolar walls, a decline in lung function and in severe cases, respiratory failure. It is believed that genetic mutations, environmental pollutants, certain medications and autoimmune diseases may play a role in IPF, but the root cause of the disease remains unknown. IPF is currently treated with antifibrotic agents but their effectiveness is limited, and mortality remains high.×
SARCOIDOSIS
Sarcoidosis is a multi-organ disorder caused by an exaggerated immune response to an unknown antigen leading to formation of granulomas (nodules of inflamed tissue) along lymphatic tracts, most commonly in the lung, heart, skin, eyes and joints. The granulomas that develop become encased in fibroblasts, which infiltrate the involved organs, potentially leading to fibrotic organ damage. While most sarcoidosis patients experience an acute form of the disease, approximately 20% of sarcoidosis patients develop a chronic form of the disease and approximately 5% progress to advanced pulmonary disease, which accounts for most of the morbidity and mortality associated with sarcoidosis. Pulmonary fibrosis due to sarcoidosis can compress pulmonary arteries, resulting in chronic hypoxia and increased vascular strain, similar to that experienced by patients with PAH. Pulmonary fibrosis in sarcoidosis patients is an independent predictor of mortality and is closely linked to the development of sarcoidosis. Currently, there are no approved treatments or treatment algorithms specifically forsarcoidosis.
×
PRIMARY FOCAL HYPERHIDROSIS DMVT-504 is a combination of the muscarinic antagonist oxybutynin with the muscarinic agonist pilocarpine. DMVT-504 uses proprietary technology to control the release and dosing of pilocarpine with the goal of reducing the frequency and severity of dry mouth and potentially other side effects associated with oxybutynin.×
ATOPIC DERMATIS AND VITILIGO Cerdulatinib is a topical dual janus kinase (JAK) and spleen tyrosine kinase (Syk) inhibitor. Dermavant is developing cerdulatinib as a topical therapy for a variety of dermatologic conditions. Dermavant believes that the profile of cerdulatinib is ideal for development in skin diseases where a growing body of evidence suggests that both JAK and Syk are important drivers of disease manifestation.×
OVERACTIVE BLADDER
URO-902 is a novel investigational gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy. URO-902 has been evaluated in two Phase 1 studies in OAB patients including a small, double-blind, placebo-controlled Phase 1b clinical trial as an intravesical injection in women with overactive bladder symptoms. Ion Channel Innovations completed the Phase 1b study in 2017 and found URO-902 to be generally well tolerated. Clinical results of the trial, which included a limited number of patients (n=13), indicated dose-dependent improvements in urinary urgency and frequency, achieving statistical significance (p<0.05) in the highdose cohort.
×
IBS-ASSOCIATED PAIN
Urovant has initiated a U.S. clinical program for vibegron for pain associated with irritable bowel syndrome (IBS) in women. Irritable bowel syndrome (IBS) is characterized by recurrent abdominal pain associated with two or more of the following: defecation, a change in frequency of stool and a change in form or appearance of stool. Additionally, IBS presents a significant health care burden and can severely impair a patient’s quality of life. There are no currently marketed drugs indicated specifically for IBS-associatedpain.
×
ATOPIC DERMATITIS
Atopic dermatitis is a chronic, pruritic inflammatory skin disease that occurs primarily in children. Both environmental and genetic factors drive disease pathology, which is characterized by breakdown of the skin barrier and concurrent inflammation. Atopic dermatitis progresses in a chronic intermittent fashion, and is characterized by periods of acute symptom worsening, known as flares, followed by periods of quiescence. Flares can be triggered by a variety of factors including infections, heat, sweating, food allergies, and anxiety. DMVT-501 is a highly potent and selective topical phosphodiesterase-4 inhibitor being evaluated for the treatment ofatopic dermatitis.
×
ACNE VULGARIS
DMVT-503 is a preclinical investigational drug candidate with a novel mechanism of action being developed for the topical treatment of acne.×
ACID CERAMIDASE DEFICIENCY Acid ceramidase deficiency, which manifests as Farber disease, is an ultra-rare lysosomal storage disease caused by a mutation in both alleles of the ASAH1 gene. This leads to the accumulation of the pro-inflammatory sphingolipid ceramide, and a macrophage driven inflammatory process causing the development of typical clinical symptoms. Like many other lysosomal storage diseases, acid ceramidase deficiency has a broad phenotypic spectrum, and is likely underdiagnosed. Farber patients typically present with the cardinal symptoms of joint contractures or arthritis, subcutaneous nodules, and weak or hoarse voice. It may take years for all three cardinal symptoms to appear together, and they may vary greatly in severity. Patients may also present with systemic inflammation (fever), severe pain, peripheral osteolysis, failure to thrive, and developmentaldelay.
Recombinant human acid ceramidase (rhAC) is an enzyme replacement therapy (ERT) under development for the treatment of acid ceramidase deficiency. Initially developed by Dr. Edward Schuchman at the Icahn School of Medicine at Mount Sinai, rhAC showed positive results in various preclinical studies. rhAC has been granted orphan drug designation by the U.S. Food and Drug Administration. Enzyvant is preparing a clinical trial in patients with acid ceramidasedeficiency.
LEARN MORE HERE
×
GENETIC DISORDERS
By developing products in-house and forming partnerships, Genevant is building a diverse pipeline of RNA therapeutics across multiple modalities. Through its proprietary LNP and ligand conjugate delivery platforms, Genevant is able to pursue mRNA, RNAi, and gene editing modalities and select the optimal approach for any given disease. Genevant expects to have 5 to 10 RNA programs in the clinic by 2020 targeting a range of genetic disorders with limited or no treatmentoptions.
×
RARE DISEASES
Genevant is pursuing the co-development and co-commercialization of five mRNA therapeutic programs for rare diseases with high unmet medical need in collaboration with BioNTech AG. The collaboration combines Genevant’s industry-leading lipid nanoparticle (LNP) delivery technology with BioNTech’s cutting-edge mRNA drug discovery platform. Both companies have established GMP-grade manufacturing capabilities and infrastructure. The companies aim to initiate clinical development in 2020.OUR PEOPLE
LEADERSHIP
* Roivant Management* Vant Leadership
* Board Members
* Advisory Group
Our leadership team includes industry veterans as well as exceptional leaders from outside of pharma.Vivek Ramaswamy
Founder & CEO
Mayukh Sukhatme MD
President, Roivant PharmaMyrtle Potter
Vant Operating Chair, Roivant PharmaFrank Torti MD
Vant Investment Chair, Roivant PharmaAdele Gulfo
Chief of Commercial Development, Roivant PharmaSam Azoulay MD
Chief Medical Officer, Roivant PharmaBenjamin Zimmer
President, Roivant HealthMatthew Gline
Chief Financial OfficerDan Rothman
Chief Information Officer Eric Venker MD, PharmD Chief Operating OfficerRakhi Kumar
Chief Accounting OfficerSascha Bucher MBA
Head of Global Transactions The management teams of our subsidiary companies feature some of the most accomplished executives in the biopharmaceutical industry.Bill Gerhart MBA
Chief Executive Officer, RespivantBill Symonds PharmD
Chief Executive Officer, AltavantBo Rode Hansen PhD
Chief Executive Officer, GenevantKeith Katkin MBA
Chief Executive Officer, UrovantLynn Seely MD
Chief Executive Officer, MyovantPaul Oppold
Chief Executive Officer, AruvantPavan Cheruvu MD
Chief Executive Officer, Axovant Pete Salzmann MD, MBA Chief Executive Officer, ImmunovantRachelle Jacques
Chief Executive Officer, EnzyvantTodd Zavodnick MBA
Chief Executive Officer, DermavantTravis May
Chief Executive Officer, DatavantWilliam H. Collier
Chief Executive Officer, ArbutusGillian Cannon PhD
President, Alyvant
John Xu PhD
President, Cytovant
Rae Yuan PhD
President, Sinovant
Ahmet Tutuncu MD, PhD EVP of Clinical & Regulatory, RespivantAlan Kimura MD, PhD
Chief Medical Officer, EnzyvantAlexander Nguyen
General Counsel, AlyvantBryan Smith
General Counsel, UrovantChris Van Tuyl
General Counsel, DermavantChristine Ocampo
Chief Accounting Officer, Urovant Cornelia Haag-Molkenteller MD, PhD Chief Medical Officer, UrovantCyril Allouche MBA
Chief Financial Officer, Dermavant David Rubenstein MD, PhD Chief Scientific Officer, DermavantElizabeth Czerepak
Chief Financial Officer, GenevantFrank Karbe
Chief Financial Officer, MyovantFraser Wright PhD
Chief Technology Advisor, AxovantGaston Picchio PhD
Chief Development Officer, ArbutusGavin Corcoran MD
Chief R&D Officer, AxovantGeorge Elston
Chief Financial Officer, Enzyvant Juan Camilo Ferreira MD Chief Medical Officer, MyovantKim Sablich MBA
Chief Commercial Officer, MyovantLyn Baranowski MBA
Chief Operating Officer, Altavant Margrit Schwarz PhD, MBA Chief Scientific Officer and Head of R&D, GenevantMat Bazley
General Counsel, AxovantMatthew Lang
General Counsel, MyovantMichael McFadden
Chief Commercial Officer, UrovantMichael Sofia PhD
Chief Scientific Officer, ArbutusMitchell Mittman
Chief Technology Officer, AlyvantMorgan Molloy
Chief Commercial Officer, EnzyvantNick Colburn MBA
Chief Financial Officer, Datavant Paris Panayiotopoulos Executive Chair, GenevantPete Zorn
Chief Operating Officer, GenevantPeter Lutwyche PhD
Chief Technology Officer, GenevantPhilip Brown MD
Chief Medical Officer, DermavantPravin Soni PhD
EVP of Development & Manufacturing, Respivant Shankar Ramaswamy MD Chief Business Officer, AxovantSteve Swank MBA
Chief Revenue Officer, DatavantTiago Girão
Chief Financial Officer, RespivantXinan Chen MD
Executive Chair, Sinovant Our directors have deep experience in pharmaceutical business development, academic research, public policy, and life sciencesinvesting.
George Bickerstaff
Axovant
Sakshi Chhabra
Roivant
Terrie Curran
Myovant
Mark Guinan MBA
Myovant
Roger Jeffs PhD
Axovant
Sef Kurstjens MD, PhDUrovant
Pierre Legault MBA
Urovant
Andrew Lo PhD
Roivant
Kenneth E. Ludlum MBADermavant
Patrick Machado
Roivant
Keith Manchester MD
Roivant
Berndt Modig MBA
Axovant
Timothy S. Nelson
Dermavant
Ilan Oren
Roivant, Axovant
Atul Pande MD
Axovant
Jim Robinson
Urovant
Kathleen Sebelius
Myovant
Members of our Public Stakeholder Advisory Group (PSAG) provide ongoing advice on how Roivant can play a role in improving thehealthcare system.
Thomas Daschle
Chairman, PSAG
Kathleen Sebelius
Participant, PSAG
Olympia Snowe
Member, PSAG
Donald Berwick MD, MPP, FRCPMember, PSAG
Sheila Burke MPA
Member, PSAG
Pete Rouse
Participant, PSAG
WHO WE WORK WITH
PARTNERS
We build our Vants through partnerships with companies and academic institutions that share our commitment to developing new medicines for patients and delivering innovation in healthcare. Select partners arelisted below.
STAY INFORMED
NEWS
__
GET IN TOUCH
CONTACT US
Basel, Switzerland
Roivant Sciences GmbHViaduktstrasse 8
4051 Basel
Switzerland
New York, NY
Roivant Sciences, Inc. 320 West 37th Street6th Floor
New York, NY 10018
United States
Durham, NC
Roivant Sciences, Inc. 324 Blackwell StreetBay 12, Suite 1220
Durham, NC 27701
United States
San Francisco, CA
Myovant Sciences, Inc. 2000 Sierra Point Parkway9th Floor
Brisbane, CA 94005
United States
Cambridge, MA
Enzyvant
55 Cambridge ParkwaySuite 900E
Cambridge, MA 02142
United States
Irvine, CA
Urovant Sciences, Inc. 5151 California AvenueSuite 250
Irvine, CA 92617
United States
Phoenix, AZ
Dermavant Sciences, Inc. 2398 East Camelback RoadSuite 1060
Phoenix, AZ 85016
United States
Warminster, PA
Arbutus Biopharma Corporation701 Veterans Circle
Warminster, PA 18974United States
San Diego, CA
Respivant Sciences, Inc. 11455 El Camino RealSuite 460
San Diego, CA 92130
United States
Vancouver, BC
Genevant Sciences Corporation 8900 Glenlyon Parkway Burnaby, British Columbia V5J 5J8Canada
Beijing, China
Sinovant Sciences
77 Jianguo Road
Room 2601-2602A
Chaoyang District
Beijing 100025
China
Shanghai, China
Sinovant Sciences
1717 Nanjing West RoadRoom 25, 42nd Floor
Jingan District
Shanhai 200040
China
REASON FOR CONTACTINGINVESTOR RELATIONSCAREERSCAMPUS RECRUITINGOTHERREASON FOR CONTACTING ____By submitting this form, you are consenting to receive an email response with relevant information from Roivant Sciences. You may also receive relevant information from us in the future. You will have the ability to opt out of receiving emails or mailings at any time. View our Privacy Policy __Join our mailing list (optional) 2019 ROIVANT SCIENCES LTD.* Privacy Policy
Follow Us
__
* Home
* Pipeline
* Leadership
* Partners
* News
* Contact us
* Join Us
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0